Author: admin

Shares of Bharat Forge are set to attract attention following the company’s announcement of a $64.5 million capital infusion into its U.S.-based subsidiaries. The move, approved by the company’s Strategic Business Investment Committee on December 23, 2024, is aimed at strengthening its operations in the United States and reducing debt burdens across its entities. According to the stock exchange filing, Bharat Forge will allocate $19.5 million directly to Bharat Forge America (BFA). Of the remaining funds, $30 million will flow into Bharat Forge Aluminum USA, a wholly owned subsidiary of BFA, and $15 million into Bharat Forge PMT Technologie, another fully owned entity under BFA. All three companies will use the capital for repaying or prepaying outstanding borrowings, thereby enhancing their financial flexibility. While the stock has delivered long-term gains, rising 7.9% over the past year and 4% in 2024 to date, it has faced notable pressure in recent months. Over the last six months, the share price has fallen 26%, with a 3-month decline of 18.11%.

Aarti Drugs shares staged a dramatic recovery on Tuesday, surging 11.12% and breaking an eight-day losing streak. The stock, which opened at ₹425.95 after Monday’s close at ₹423.95, remained flat through most of the session. But a late-hour rally saw it skyrocket to an intraday high of ₹495.55 before settling at ₹471.10, making it the top gainer among group A stocks. The surge came on the heels of an announcement that Aarti Drugs received an Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility in Tarapur, Maharashtra. The report confirmed that the facility, which produces key APIs like Ciprofloxacin HCl, Zolpidem Tartrate, and Celecoxib, is classified as “voluntary action indicated” (VAI). This rating signifies minimal compliance issues and clears the way for exports to the lucrative US market. Despite Tuesday’s gains, Aarti Drugs has had a tough year, with the stock down 4% year-to-date. If the upward momentum continues, December could mark the end of a prolonged losing streak.

Greaves Cotton shares electrified the market on Tuesday, jumping nearly 10% after its subsidiary, Greaves Electric Mobility Limited, revealed plans for a ₹1,000 crore IPO. The company filed a Draft Red Herring Prospectus (DRHP) with SEBI, BSE, and NSE on December 23, 2024, marking a significant step toward strengthening its foothold in the electric mobility space. The IPO will include a fresh issue of equity shares and an offer for sale by major stakeholders, including Abdul Latif Jameel Green Mobility Solutions DMCC and Greaves Cotton itself. On the BSE, Greaves Cotton shares opened at ₹236.80, shot up to ₹256.30 intraday, and touched a low of ₹229.70. The stock has been on a robust upward trajectory, surging from ₹160 to ₹260 in November alone. Greaves Cotton’s bold strategy highlights its commitment to innovation and scaling up in the electric vehicle sector, a market with immense potential. This IPO not only promises to solidify its market position but also serves as a rallying point for investors eager to ride the EV wave.

The Securities and Exchange Board of India (SEBI) cracked down hard on Bharat Global Developers Ltd., suspending trading of its shares over accusations of manipulating stock prices with fake disclosures and accounting fraud. The Gujarat-based firm allegedly fabricated claims of securing massive orders from big names like Reliance Industries, Tata Group, and McCain India Agro, which propelled its shares by a staggering 10,000% in just a year. SEBI’s investigation revealed these “high-value orders” were smoke and mirrors, strategically timed to benefit a select group of investors who participated in preferential share offerings. This is just the latest in a string of fraud cases targeting India’s vibrant but increasingly risky equity market. The regulator recently tightened rules for smaller company listings to curb such abuses, canceling IPOs and delaying others amidst allegations of shady dealings. SEBI’s actions against Bharat Global include barring involved parties from the capital markets and impounding illicit gains.

Tata Group stocks lit up the BSE on December 24, riding a wave of excitement over reports that the conglomerate is preparing to launch the IPO of its financial services arm, Tata Capital. Tata Investment Corporation soared 12%, while Tata Technologies climbed 4%. Other Tata entities joined the party, with Tata Chemicals up 3%, Tata Motors rising 2%, and TCS inching up 1%. According to a Moneycontrol report, the group is already in talks with advisors for this blockbuster IPO, likely exceeding ₹15,000 crore. The IPO would fulfill the Reserve Bank of India’s (RBI) mandate requiring “upper-layer” non-banking financial companies (NBFCs) to list within three years of notification. The group has reportedly engaged legal powerhouse Cyril Amarchand Mangaldas and investment bank Kotak Mahindra Capital to lead the charge. This IPO is expected to be a show-stopper, given Tata Capital’s strong positioning in India’s financial ecosystem. Its compliance with RBI norms not only underscores the group’s adaptability but also reflects its strategic intent to leverage public markets for growth.

PG Electroplast shares surged 5.5% in early trading on December 24, hitting ₹1,002, as the company announced a strategic tie-up with Whirlpool of India. The agreement, revealed through a regulatory filing, positions PG Electroplast as a contract manufacturer for select Whirlpool-branded semi-automatic washing machines. PG Electroplast has cemented its reputation as a leading player in India’s electronic manufacturing services (EMS) space, working with top consumer durables and electronics brands. They’re betting on expanded capacities and capabilities to sustain their dominance in the consumer durables and plastics sector. To match this optimism, the company revised its FY25 revenue guidance to ₹4,250 crore—a remarkable 54.7% jump from FY24 levels. Net profit projections are equally ambitious, expected to climb 82.5% year-over-year to ₹250 crore. Operational efficiencies and robust cash flow management underpin these forecasts.

Biocon’s shares soared 5% on Tuesday, December 24, closing at ₹344.80 after hitting an intraday high of ₹347.35. The rally was fueled by two significant developments that strengthened investor confidence in the company’s growth trajectory. The first boost came from the United States Food and Drug Administration (USFDA), which issued an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status for Biocon’s Active Pharmaceutical Ingredients (API) facility in Bengaluru. Adding further momentum, Biocon announced that its European partner, Zentiva, received a decentralised procedure approval in the European Union (EU) for Liraglutide, a complex formulation used to treat Type-2 diabetes and manage weight. Biocon’s stock, which has already gained 35% year-to-date, reflected the optimism around these developments. The Bengaluru-based biopharma giant is clearly on a roll, leveraging strategic partnerships and regulatory approvals to solidify its presence in both the API and biosimilar markets.

Avaada Group is setting its sights on raising $1 billion (over ₹8,400 crore) in debt by March next year to fund its ambitious green energy projects, including wind, solar, and battery storage initiatives. Chairman Vineet Mittal shared with FE that the group has already raised equity and is now turning to debt to accelerate its growth. With an operational capacity of 4.7 gigawatts (GW), Avaada is targeting 11 GW by 2026 and 30 GW by 2030. Mittal emphasized that achieving 30 GW could happen sooner if the necessary transmission lines are developed. The group’s energy portfolio also includes 5 gigawatt-hours (GWh) of battery storage and 10 GWh of long-duration pumped hydel storage. Alongside its solar ventures, Avaada has an operational 1.5 GW solar plant in Noida. In parallel, Tata Power has also invested in solar manufacturing, with a 4 GW solar cell and module plant in Tamil Nadu that began operations last year. Additionally, Avaada is expanding into green ammonia and green hydrogen projects in Gopalpur, Odisha, with $1.8 billion secured from REC to fund its production facility in the Gopalpur Industrial Park.

Shares of Intellect Design Arena rallied 13% on Monday, December 23, reaching an intraday high of ₹925.55, as investors cheered the company’s newly launched Enterprise AI platform, Purple Fabric. The surge comes on the heels of a detailed presentation on December 19, where the company introduced the platform designed to revolutionize operations in the financial and insurance sectors. Purple Fabric stands out for its ‘Multi-Agent’ AI system, which aims to streamline enterprise processes like claims settlement and tackle the growing data complexity in financial services. Built on Large Language Models (LLMs), the platform promises intuitive data integration and classification, empowering organizations to deliver seamless customer experiences without requiring deep technical expertise. The stock, now 23% shy of its 52-week high of ₹1,198.80 from March 2024, has rebounded impressively, up 33% from its November low of ₹693.05. December alone has seen a sharp 28% climb, marking a turnaround after three consecutive months of losses.